Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BeNeBio dose reduction study of IL-17 and IL-23 biologics in psoriasis
NL-OMON52624Phase 4Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- Aug 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in psoriasis and plaque psoriasis (2 arms), sponsored by Amsterdam University Medical Center. Primary endpoint: Cumulative incidence of persistent flares. Started Aug 2020; status: completed.
02
Conditions
psoriasisplaque psoriasis
Beyond the preview
Go deeper on NL-OMON52624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON52624.